United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. Our lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as Hepatitis C. For more information about United Therapeutics' pipeline, click here

To receive press releases, quarterly and annual SEC filings, please click here.

Current Press Releases

Dec 27, 2011
Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union

Oct 27, 2011
United Therapeutics Corporation Reports Third Quarter 2011 Financial Results

more »

Events

Feb 27, 2012
Collins Stewart Orphan Drug Day

Feb 27, 2012
2012 Citi Global Healthcare Conference

Jun 4, 2012
Jefferies 2012 Global Healthcare Conference in New York City

more »